medigraphic.com
Revista Médica Sinergia

2021, Number 06

<< Back Next >>

Revista Médica Sinergia 2021; 6 (06)

Overview of serotonin toxicity

Orozco GR, Garnier FJC, Pizarro AG

Language: Spanish
References: 22
Page: 1-12
PDF size: 205.46 Kb.


ABSTRACT

Serotonin syndrome / serotonin intoxication is a life-threatening clinical condition, triggered by the use of drugs with serotonin activity or its activity on serotoninergic receptors, while it can occur through the therapeutic use of this types of drugs, it can also occur by intentional overdose or through pharmacological interaction through different pharmacological mechanisms of action. The clinical picture presents as a combination of mental status changes, neuromuscular hyperactivity and a profuse activity of the autonomic nervous system. Diagnosis is based on a detailed medical history and physical examination with an emphasis on ongoing medications and drug use and supported by laboratory tests. Treatment is based mainly on supportive measures and pharmacological antagonism, with vital importance in early recognition and management to avoid complications.


REFERENCES

  1. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020 Jan;124(1):44–62.

  2. Prakash S, Rathore C, Rana K, Prakash A. Fatal serotonin syndrome: a systematic review of 56 cases in the literature. Clin Toxicol. 2021 Feb 1;59(2):89–100.

  3. Macedo D, Filho AJMC, Soares de Sousa CN, Quevedo J, Barichello T, Júnior HVN, et al. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord. 2017 Jan;208:22–32.

  4. Talton C. Serotonin Syndrome/Serotonin Toxicity. Fed Pract [Internet]. 2020 Oct 10 [cited 2021 Mar 20];(Vol 37 No 10). Available from: https://www.mdedge.com/fedprac/article/229630/hospital-medicine/serotonin-syndrome/serotonin-toxicity

  5. Bartlett D. Drug-Induced Serotonin Syndrome. Crit Care Nurse. 2017 Feb 1;37(1):49–54.

  6. Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016 Nov;83(11):810–7.

  7. FDA Adverse Events Reporting System (FAERS) Public Dashboard - FDA Adverse Events Reporting System (FAERS) Public Dashboard | Sheets - Qlik Sense [Internet]. [cited 2021 Mar 21]. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

  8. Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018 Nov;131(11):1382.e1-1382.e6.

  9. Karkow DC, Kauer JF, Ernst EJ. Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. J Clin Psychopharmacol. 2017 Oct;37(5):518–23.

  10. Fouquet G, Coman T, Hermine O, Côté F. Serotonin, hematopoiesis and stem cells. Pharmacol Res. 2019 Feb;140:67–74.

  11. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. Int J Tryptophan Res. 2019 Jan;12:117864691987392.

  12. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2019 May 9;20(9):2288.

  13. Bartakke A, Corredor C, van Rensburg A. Serotonin syndrome in the perioperative period. BJA Educ. 2020 Jan;20(1):10–7.

  14. Foong A-L, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). :8.

  15. Simon LV, Keenaghan M. Serotonin Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Mar 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482377/

  16. Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases. BMC Neurol. 2016 Dec;16(1):97.

  17. Jurek L, Nourredine M, Megarbane B, d’Amato T, Dorey J-M, Rolland B. Le syndrome sérotoninergique : une revue actualisée de la littérature. Rev Médecine Interne. 2019 Feb;40(2):98–104.

  18. Ansari H, Kouti L. Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment. Curr Pain Headache Rep. 2016 Aug;20(8):50.

  19. Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced Serotonin Syndrome. Intern Med. 2017 Mar 15;56(6):737–9.

  20. Uddin MF, Alweis R, Shah SR, Lateef N, Shahnawaz W, Ochani RK, et al. Controversies in Serotonin Syndrome Diagnosis and Management: A Review. J Clin Diagn Res JCDR. 2017 Sep;11(9):OE05–7.

  21. Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. In: Handbook of Clinical Neurology [Internet]. Elsevier; 2018 [cited 2021 Mar 23]. p. 663–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444640741000392

  22. Bruggeman C, O’Day CS. Selective Serotonin Reuptake Inhibitor Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Mar 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534815




2020     |     www.medigraphic.com